ReviewHuman psychopharmacology2022
N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.
Review in Human psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 41 citations in OpenAlex.
- Pharmacodynamic effects and plasma pharmacokinetics of N, N-dimethyltryptamine after intranasal versus subcutaneous administration in male rats.Psychopharmacology · 2026Article
- Combined Neuroprotective Effects of N,N-Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats.Journal of neurochemistry · 2026Article
- The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study.Frontiers in psychiatry · 2026Article
- Development and validation of an analytical method for the determination of select 4-position ring-substituted tryptamines in plasma by liquid chromatography-tandem mass spectrometry.Journal of analytical toxicology · 2025Article
- Oceanic states of consciousness-an existential-neuroscience perspective.Frontiers in human neuroscience · 2025Article
- Drug-induced psychosis following use of Ayahuasca: a presentation to forensic psychiatric services.BMJ case reports · 2024Article
- The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Review
- The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.International journal of molecular sciences · 2023Review
- Interpol Review of Drug Analysis 2019-2022.Forensic science international. Synergy · 2023Review
- Application of DeuteratedACS medicinal chemistry letters · 2022Article
- Corrigendum.Human psychopharmacology · 2022Article
- N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.Human psychopharmacology · 2022Review
- 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs.Frontiers in psychiatry · 2022Review
- Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study.Frontiers in pharmacology · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issuedCorrigendum.2022
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveReports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post-traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N-dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of selected literature regarding the mechanisms of action of DMT and ayahuasca; and assess to what extent the state of research can explain reports of unusual phenomenology.
designA narrative review.
resultsCompounds in ayahuasca have been found to bind to serotonergic receptors, glutaminergic receptors, sigma-1 receptors, trace amine-associated receptors, and modulate BDNF expression and the dopaminergic system. Subjective effects are associated with increased delta and theta oscillations in amygdala and hippocampal regions, decreased alpha wave activity in the default mode network, and stimulations of vision-related brain regions particularly in the visual association cortex. Both biological processes and field of consciousness models have been proposed to explain subjective effects of DMT and ayahuasca, however, the evidence supporting the proposed models is not sufficient to make confident conclusions. Ayahuasca plant medicine and DMT represent potentially novel treatment modalities.
conclusionsFurther research is required to clarify the mechanisms of action and develop treatments which can be made available to the general public. Integration between healthcare research institutions and reputable practitioners in the Amazon is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.